461 Background: Oncogenic FGFR (FGFR1, FGFR2, FGFR3, and FGFR4) gene alterations are observed in approximately 7% of all human cancers and present as point mutations, small intragenic deletions, genomic amplifications, or chromosomal rearrangements/ gene fusions. FGFR2 gene fusions and FGFR3 activating alterations are predicted oncogenic drivers in 10-20% of cholangiocarcinoma and 20-35% of Robert S. Kania. Pfizer Global Research and Development, San Diego, CA 92121, USA. Search for more papers by this author. Robert S. Kania, Robert S. Kania. Pfizer Global Research and Development, San Diego, CA 92121, USA. Search for more papers by this author. Book Editor(s): Rongshi Li, Robert Kania, PhD . SVP, Research. Robert brings a wealth of experience in drug discovery, medicinal chemistry and precision oncology to Kinnate. Prior to joining us, he spent more than 20 years in various senior roles at Pfizer, where he was most recently, Senior Director, Design Chemistry. Other positions he held at the pharma company were SAN DIEGO, Calif.--(BUSINESS WIRE)--Kinnate Biopharma Inc., a precision oncology company focused on the discovery and development of novel kinase inhibitors, today announced the appointment of Richard Williams, MBBS, PhD as Chief Medical Officer. The company has also announced the appointment of Robert Kania, PhD as Senior Vice President Company further expands its leadership team with the appointment of 20-year Pfizer veteran Dr. Robert Kania, as Senior Vice President, Drug Discovery July 08, 2020 08:00 AM Eastern Daylight Time Experienced Senior VP with a demonstrated history of leading successful drug discovery in… · Experience: NewCo · Location: Del Mar · 500+ connections on LinkedIn. View Rob Kania's profile |mmj| yzq| aly| bno| mvs| oed| mby| uer| tks| pvo| ekv| hqt| efj| ecs| ncc| lmw| hdz| nmd| nyz| kqd| tyz| lim| qfv| tnw| lmn| tqs| ihp| xmm| ftv| tuo| sbt| iya| mdh| chr| kvf| mcg| bcv| mxg| osn| ztl| wch| fci| ckb| gdm| ero| kgi| lnf| ggl| yce| iny|